1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2022, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 7, 17 and 7 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects, 2022
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products, 2022
- Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- ABL Bio Inc
- AC Immune SA
- Allyx Therapeutics Inc
- Alterity Therapeutics Ltd
- Aprinoia Therapeutics Inc
- Arvinas Inc
- Asha Therapeutics LLC
- Asklepios BioPharmaceutical Inc
- AstraZeneca Plc
- Biohaven Pharmaceutical Holding Company Ltd
- Coave Therapeutics
- Corestem Inc
- Denali Therapeutics Inc
- Genmab AS
- ICB International Inc
- Inhibikase Therapeutics Inc
- Ionis Pharmaceuticals Inc
- iRegene Therapeutics Co Ltd
- Kainos Medicine Inc
- MitoDys Therapeutics Ltd
- Neuramedy Co Ltd
- Newron Pharmaceuticals SpA
- NysnoBio LLC
- PharmaKure Ltd
- ProMIS Neurosciences Inc
- Stealth BioTherapeutics Corp
- Teva Pharmaceutical Industries Ltd
- UCB SA
- Vaxxinity Inc
- Yoda Pharmaceuticals Inc
